The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Using the tumor microenvironment to identify predictors of immunotoxicity to checkpoint inhibitors.
 
William Alexander
No Relationships to Disclose
 
Kristopher Attwood
No Relationships to Disclose
 
Kayla Catalfamo
No Relationships to Disclose
 
Grace K. Dy
Honoraria - AstraZeneca/MedImmune; GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Takeda
Research Funding - AMGEN (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Tesaro (Inst)
 
Saby George
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Merck; Pfizer; QED Therapeutics; Sanofi; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst)
 
Marc S. Ernstoff
Stock and Other Ownership Interests - Bristol-Myers Squibb; GE Healthcare
Consulting or Advisory Role - Alkermes; Bristol-Myers Squibb; EMD Serono; ImmuNext; Omniseq
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); EMD Serono; Merck (Inst); Merrimack (Inst)
Travel, Accommodations, Expenses - Alkermes; ImmuNext
Other Relationship - Bristol-Myers Squibb
 
Yara Abdou
No Relationships to Disclose